ArticleJournal of clinical pathology1993
Prognostic value of epidermal growth factor receptor expression in cervical carcinoma.
Article in Journal of clinical pathology, 1993. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 88 citations in OpenAlex.
- Phase II study of cisplatin plus cetuximab in advanced, recurrent, and previously treated cancers of the cervix and evaluation of epidermal growth factor receptor immunohistochemical expression: a Gynecologic Oncology Group study.Gynecologic oncology · 2011Trial
- EGFR and HER2 expression in cervical cancer patients in Ibadan, Nigeria.Ecancermedicalscience · 2023Article
- A systematic review and meta-analysis of the prevalence of therapeutic targets in cervical cancer.Ecancermedicalscience · 2021Review
- Mutation analysis of EGFR and its correlation with the HPV in Indian cervical cancer patients.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- Tumor cavitation among lung cancer patients receiving first-line chemotherapy at a tertiary care centre in India: association with histology and overall survival.Medical oncology (Northwood, London, England) · 2013Article
- EGFR gene amplification is related to adverse clinical outcomes in cervical squamous cell carcinoma, making the EGFR pathway a novel therapeutic target.British journal of cancer · 2011Article
- Monoclonal antibodies in gynecological cancer: a critical point of view.Clinical & developmental immunology · 2011Review
- Molecular characterization of EGFR, PDGFRA and VEGFR2 in cervical adenosquamous carcinoma.BMC cancer · 2009Article
- Do tumor cavitation and sex in resected stage I non-small-cell lung cancer correlate with prognosis?World journal of surgery · 2009Article
- EGFR and HER2 expression in primary cervical cancers and corresponding lymph node metastases: implications for targeted radiotherapy.BMC cancer · 2008Article
- Epidermal growth factor receptor inhibition in cancer therapy: biology, rationale and preliminary clinical results.Investigational new drugs · 1999Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsTo investigate the pattern of epidermal growth factor receptor expression and its prognostic value in the three main types of cervical carcinoma.
methods62 cases of stage IB/IIA cervical carcinoma, all with a minimum of five years of follow up, were studied. Representative sections were stained for mucin to permit accurate tumour typing and a standard avidin-biotin immunoperoxidase technique using the polyclonal antibody 12E was used to demonstrate the presence of epidermal growth factor receptor.
resultsA proportion of all three tumour types expressed epidermal growth factor receptor, it being most common in squamous cell carcinomas (50%). Overall, there was a correlation between epidermal growth factor expression and mortality. This was particularly obvious in the absence of lymph node metastases. When the individual tumour types were considered this association with prognosis was not demonstrable for squamous cell carcinomas or adenocarcinomas but was a very prominent feature of adenosquamous carcinomas.
conclusionsImmunohistochemical demonstration of epidermal growth factor receptor expression may be useful in identifying those patients with a poor prognosis, particularly those with adenosquamous carcinomas which have not metastasised to the regional lymph nodes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.